Nisa Investment Advisors LLC Reduces Stock Position in Catalent, Inc. (NYSE:CTLT)

Nisa Investment Advisors LLC cut its stake in shares of Catalent, Inc. (NYSE:CTLT) by 87.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 7,280 shares of the company’s stock after selling 50,268 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Catalent were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cetera Advisor Networks LLC boosted its holdings in shares of Catalent by 7.1% in the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after buying an additional 130 shares during the last quarter. Mackay Shields LLC grew its position in shares of Catalent by 0.6% during the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after acquiring an additional 149 shares during the period. Wetherby Asset Management Inc. increased its stake in shares of Catalent by 5.1% in the 1st quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company’s stock worth $557,000 after purchasing an additional 243 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its holdings in Catalent by 1.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company’s stock worth $953,000 after purchasing an additional 252 shares during the period. Finally, Covestor Ltd lifted its position in Catalent by 84.9% during the first quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after purchasing an additional 258 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CTLT. StockNews.com began coverage on Catalent in a research note on Friday. They issued a “sell” rating on the stock. Barclays lifted their price target on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. UBS Group restated a “neutral” rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Price Performance

NYSE:CTLT opened at $55.77 on Friday. The business’s 50-day moving average is $56.83 and its 200 day moving average is $48.16. Catalent, Inc. has a 12 month low of $31.45 and a 12 month high of $60.20. The company has a market capitalization of $10.09 billion, a P/E ratio of -8.20, a P/E/G ratio of 6.02 and a beta of 1.20. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period last year, the company earned $0.62 earnings per share. The firm’s revenue was down 10.2% on a year-over-year basis. On average, equities research analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.